Cart
sales@molnova.com
Obexelimab
CAS No. 1690307-05-1
Obexelimab( —— )
Catalog No. M37299 CAS No. 1690307-05-1
Obexelimab (XmAb5871) is a humanized, Fc-engineered anti-CD19 antibody with enhanced affinity for FcγRIIb, utilized in the study of autoimmune diseases .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 687 | In Stock |
|
| 10MG | 937 | In Stock |
|
| 25MG | 1416 | In Stock |
|
| 50MG | 1832 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameObexelimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionObexelimab (XmAb5871) is a humanized, Fc-engineered anti-CD19 antibody with enhanced affinity for FcγRIIb, utilized in the study of autoimmune diseases .
-
DescriptionObexelimab (XmAb5871) is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Obexelimab can be used in research of autoimmune.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1690307-05-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chu SY, et, al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014 May;66(5):1153-64.?
molnova catalog
related products
-
3-Geranyl-3-prenyl-2...
3'-Geranyl-3-prenyl-2',4',5,7-tetrahydroxyflavone is a natural product from Morus alba.
-
(D-Arg1,D-Pro2,D-Phe...
(D-Arg1,D-Pro2,D-Phe7,D-His9)-Substance P is a selective NK1 receptor antagonist.
-
Roemerine
Roemerine is a potential active xanthine oxidase(XOD) inhibitor, XOD is a key enzyme in the pathogenesis of hyperuricemia and also a well-known target for the drug development to treat gout.
